Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Scilex Holding Company ( (SCLX) ).
On November 3, 2025, Scilex Holding Company entered into a License Agreement with Datavault AI Inc., granting Scilex a worldwide, exclusive license to Datavault’s AI-driven technology for use in the biotech and biopharma industries. This agreement enables Scilex to utilize Datavault’s advanced data platforms for secure tokenization and monetization of biotech assets, marking a significant advancement in the commercialization of biotech innovations. The license agreement includes a non-refundable fee of $10 million, payable in installments, and potential milestone payments up to $2.55 billion. This strategic move positions Scilex to potentially revolutionize the pharmaceutical industry by creating a Biotech Exchange platform and exploring opportunities to tokenize pharmaceutical drug and diagnostic sales.
The most recent analyst rating on (SCLX) stock is a Buy with a $770.00 price target. To see the full list of analyst forecasts on Scilex Holding Company stock, see the SCLX Stock Forecast page.
More about Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases. The company targets indications with high unmet needs and large market opportunities, offering non-opioid therapies to improve patient outcomes. Scilex’s commercial products include ZTlido®, ELYXYB®, and Gloperba®, and it is developing additional product candidates such as SP-102, SP-103, and SP-104.
Average Trading Volume: 244,894
Technical Sentiment Signal: Sell
Current Market Cap: $135.5M
For detailed information about SCLX stock, go to TipRanks’ Stock Analysis page.